CYCC Cyclacel Pharmaceuticals
- 2.2381
- -0.4019-15.22%
Cyclacel Pharmaceuticals News
Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer
- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma -BERKELEY HEIGHTS, N.J., June 0
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSharps Technology (NASDAQ:STSS) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. Cyclacel Pharmaceuticals (NASDA
Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Earnings Call Summary | Cyclacel Pharmaceuticals(CYCC.US) Q1 2024 Earnings Conference
The following is a summary of the Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript:Financial Performance:Cyclacel reported cash and cash equivalents of $9.9 million as of the end
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript
10-Q: Quarterly report
Express News | Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K
Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000
04:06 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000
Press Release: Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update - New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Stra
Notable Earnings After Tuesday's Close
AMC, LAZR and OCGN Are Among Premarket Gainers
Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Shares of JanOne Inc. (NASDAQ:JAN) rose sharply in today's pre-market trading after the company announced plans to acquire ALT 5 Sigma Inc.The deal is projected to close in the week of May 13th.JanOne
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Express News | Cyclacel Pharmaceuticals Inc Files for Resale of up to 15.2 Mln Shares by the Selling Stockholders - SEC Filing
Cyclacel Pharmaceuticals Is Maintained at Buy by Roth MKM
Cyclacel Pharmaceuticals Is Maintained at Buy by Roth MKM
Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Lowers Price Target to $11
Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and lowers the price target from $21 to $11.
Cyclacel Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 354.55% Roth MKM $21 → $11 Maintains Buy 12/19/2023 — Brookline Capital Downgrades Buy → Hold
Express News | Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced at-the-Market Under Nasdaq Rules
Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Shares of Pinterest, Inc (NYSE:PINS) rose sharply in today's pre-market trading following strong first-quarter earnings and upbeat second-quarter guidance.Pinterest's first-quarter revenue increased n
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersAkanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix (NASDAQ:NAOV) shares moved upwar
Analysis
Price Target
No Data
